The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma

June 7, 2025 updated by: jiahong Deng

The Role of Surgical Resection AND Stereotactic Radiosurgery in PCNS-DLBCL: A Retrospective Analysis of Clinical Benefits

The objective of this observational study is to understand the long-term impact of surgery and gamma knife treatment on primary central diffuse large B-cell lymphoma. The main questions it aims to answer are:

Can surgery and gamma knife prolong the survival period of patients with primary central diffuse large B-cell lymphoma? Participants who have already incorporated surgery and gamma knife as part of the routine medical care for patients with primary central diffuse large B-cell lymphoma will answer questions about survival period within 5 years.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

76

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

A retrospective analysis was conducted on data from patients diagnosed with primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) at Nanfang Hospital between December 2006 and December 2023. A total of 76 patients were included in this study, with follow-up continuing until July 2024.

Description

Inclusion Criteria:

pathologically confirmed PCNS-DLBCL complete clinical records detailing treatment methods and surgical approaches.

Exclusion Criteria:

incomplete systemic treatment data loss to follow-up after initial contact prior receipt of whole-brain radiotherapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
primary central nervous system diffusing large cell lymphoma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival
Time Frame: December 2006 and December 2023
The time from diagnosis to death of the patient
December 2006 and December 2023

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

jiahong Deng

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2006

Primary Completion (Actual)

December 1, 2023

Study Completion (Actual)

May 1, 2025

Study Registration Dates

First Submitted

May 28, 2025

First Submitted That Met QC Criteria

May 28, 2025

First Posted (Actual)

June 6, 2025

Study Record Updates

Last Update Posted (Actual)

June 11, 2025

Last Update Submitted That Met QC Criteria

June 7, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NFEC-2025-095

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Central Nervous System Diffusing Large Cell Lymphoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe